SCHEMBL2946296

SCHEMBL2946296

CC1CCc2c(sc3nc4n(c(=O)c23)CCCCC4)C1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.71
RAB9A P51151 9/20 0.71
NPC1 O15118 8/20 0.71
HPGD P15428 5/20 0.71
MAPT P10636 4/20 0.71
SMN1; SMN2 Q16637 3/20 0.71
LMNA P02545 3/20 0.71
HSD17B10 Q99714 2/20 0.71
ALOX15 P16050 1/20 0.71
POLB P06746 3/20 0.70
TSHR P16473 3/20 0.67
GAA P10253 2/20 0.67
CASP1 P29466 1/20 0.67
KDM4E B2RXH2 3/20 0.60
MEN1 O00255 1/20 0.60
BLM P54132 1/20 0.60
GFER P55789 1/20 0.60
KMT2A Q03164 1/20 0.60
TDP1 Q9NUW8 1/20 0.60
HSP90AA1 P07900 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2951746 0.86 ALDH1A1 (0.65) ALDH1A1RAB9ANPC1HPGDMAPT
SCHEMBL13154693 0.83 ALDH1A1 (1.00) ALDH1A1RAB9ANPC1HPGDMAPT
SCHEMBL2950818 0.83 ALDH1A1 (1.00) ALDH1A1RAB9ANPC1HPGDMAPT
SCHEMBL2950756 0.83 ALDH1A1 (1.00) ALDH1A1RAB9ANPC1HPGDMAPT
SCHEMBL2953501 0.82 ALDH1A1 (1.00) ALDH1A1RAB9ANPC1HPGDMAPT
SCHEMBL2947859 0.82 SMN1; SMN2 (1.00) ALDH1A1RAB9ANPC1HPGDMAPT
SCHEMBL2951765 0.82 SMN1; SMN2 (0.70) ALDH1A1RAB9ANPC1HPGDMAPT
SCHEMBL2949673 0.80 ALDH1A1 (0.76) ALDH1A1RAB9ANPC1HPGDMAPT
SCHEMBL2951654 0.79 LMNA (0.97) ALDH1A1RAB9ANPC1HPGDMAPT
SCHEMBL2951772 0.78 RAB9A (0.71) ALDH1A1RAB9ANPC1HPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100249106-A1 Methods of Making and Using Therapeutically Active Thiophenepyrimidinone Compounds SOLVAY PHARMACEUTICALS B.V. (NL) 2010-09-30 US disclosed
US-20100249106-A1 Methods of Making and Using Therapeutically Active Thiophenepyrimidinone Compounds SOLVAY PHARMACEUTICALS B.V. (NL) 2010-09-30 US disclosed
US-20100249106-A1 Methods of Making and Using Therapeutically Active Thiophenepyrimidinone Compounds SOLVAY PHARMACEUTICALS B.V. (NL) 2010-09-30 US disclosed
US-7754709-B2 Tetracyclic thiophenepyrimidinone compounds as inhibitors of 17β hydroxysteroid dehydrogenase compounds SOLVAY PHARMACEUTICALS BV (NL) 2010-07-13 US disclosed
US-7754709-B2 Tetracyclic thiophenepyrimidinone compounds as inhibitors of 17β hydroxysteroid dehydrogenase compounds SOLVAY PHARMACEUTICALS BV (NL) 2010-07-13 US disclosed
US-7754709-B2 Tetracyclic thiophenepyrimidinone compounds as inhibitors of 17β hydroxysteroid dehydrogenase compounds SOLVAY PHARMACEUTICALS BV (NL) 2010-07-13 US disclosed
EP-1635840-B1 THIOPHENEPYRIMIDINONES AS 17-BETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS SOLVAY PHARM BV (NL) 2008-07-23 EP disclosed
EP-1635840-B1 THIOPHENEPYRIMIDINONES AS 17-BETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS SOLVAY PHARM BV (NL) 2008-07-23 EP disclosed
US-20080103131-A1 Therapeutically Active Thiophenepyrimidinone Compounds and Their Use SOLVAY PHARMACEUTICALS B.V. (NL) 2008-05-01 US disclosed
US-20080103131-A1 Therapeutically Active Thiophenepyrimidinone Compounds and Their Use SOLVAY PHARMACEUTICALS B.V. (NL) 2008-05-01 US disclosed
US-20080103131-A1 Therapeutically Active Thiophenepyrimidinone Compounds and Their Use SOLVAY PHARMACEUTICALS B.V. (NL) 2008-05-01 US disclosed
US-20050032778-A1 Therapeutically active thiophenepyrimidinone compounds and their use SOLVAY PHARMACEUTICALS B.V. (NL) 2005-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032778-A1 Therapeutically active thiophenepyrimidinone compounds and their use HSD17B1, HSD17B3, HSD17B2 ALDH1A1 133/4885RAB9A 3542/4885NPC1 1472/4885
US-20100249106-A1 Methods of Making and Using Therapeutically Active Thiophenepyrimidinone Compounds HSD17B3, HSD17B1, HSD17B2 ALDH1A1 139/4885RAB9A 4047/4885NPC1 1504/4885
US-20080103131-A1 Therapeutically Active Thiophenepyrimidinone Compounds and Their Use HSD17B1, HSD17B3, HSD17B2 ALDH1A1 133/4885RAB9A 3542/4885NPC1 1472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.